TY - JOUR
T1 - Clinical importance of neutralising antibodies against interferon beta in patients with relapsing-remitting multiple sclerosis
AU - Sorensen, Per Soelberg
AU - Ross, Christian
AU - Clemmesen, Katja Maria
AU - Bendtzen, Klaus
AU - Frederiksen, Jette Lautrup
AU - Jensen, Kai
AU - Kristensen, Ole
AU - Petersen, Thor
AU - Rasmussen, Soren
AU - Ravnborg, Mads
AU - Stenager, Egon
AU - Koch-Henriksen, Nils
AU - Danish Multiple Sclerosis Study Group
PY - 2003/10/11
Y1 - 2003/10/11
N2 - Interferon beta is the first-line treatment for relapsing-remitting multiple sclerosis, but the drug can induce neutralising antibodies against itself, which might reduce effectiveness. We aimed to assess the clinical effect of neutralising antibodies.
AB - Interferon beta is the first-line treatment for relapsing-remitting multiple sclerosis, but the drug can induce neutralising antibodies against itself, which might reduce effectiveness. We aimed to assess the clinical effect of neutralising antibodies.
U2 - 10.1016/S0140-6736(03)14541-2
DO - 10.1016/S0140-6736(03)14541-2
M3 - Journal article
C2 - 14568740
VL - 362
SP - 1184
EP - 1191
JO - Lancet
JF - Lancet
SN - 0140-6736
IS - 9391
ER -